Navigation Links
DURECT Announces Changes to its Board of Directors
Date:9/27/2013

CUPERTINO, Calif., Sept. 27, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26, 2013.  Separately, Michael Casey has made the decision to retire from the Board of Directors effective December 31, 2013. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

Mr. Shepard has over 30 years' experience in the pharmaceutical, biotechnology and drug delivery fields.  Mr. Shepard currently serves as an Executive Partner at Sofinnova Ventures.  From 2010 until 2012, he was President and CEO of NextWave Pharmaceuticals, a pediatric focused therapeutics company which was acquired in November 2012 by Pfizer in a deal valued up to $700 million shortly after NextWave obtained FDA approval for Quillivant XR, a treatment for Attention-Deficit Hyperactivity Disorder (ADHD).  While serving at NextWave, Mr. Shepard maintained a strategic adviser relationship with Sofinnova Ventures, which he joined in 2008 as an Executive in Residence.  Prior to Sofinnova Ventures, Mr. Shepard was President and CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen for $420 million.  He then helped with Ilypsa's spin-out company, Relypsa, serving as interim President and CEO.  Before Ilypsa, Mr. Shepard served as Vice President, Commercial Operations at Telik, where he was responsible for all activities related to market preparation toward the launch of the company's lead oncology compounds.  Previously, he was Vice President of ALZA Pharmaceuticals' Oncology Business Unit, having held leadership positions of increasing responsibility in the establishment and operation of ALZA's specialty pharmaceutical sales and marketing group.  Mr. Shepard began his career in pharmaceutical sales and marketing at Ortho Pharmaceutical and Syntex Laboratories.     

"We look forward to the commercial perspective Jay Shepard will bring to our Board of Directors as we evaluate and execute on the partnering, development opportunities and market introduction for our product pipeline," said Dr. Felix Theeuwes, DURECT's Chairman and Chief Scientific Officer. "Mike Casey has decided to retire from our Board at the end of the year in order to spend additional time pursuing personal interests.  We have benefited greatly from Mike Casey's commercial insight during his 9 years of dedicated service as a member of the Board of Directors, and we thank him for his valuable counsel and strategic input to the Company."

"This is a very exciting time for DURECT, given the February 2014 PDUFA date for POSIDUR and the other programs in development, and I look forward to assisting management and the Board of Directors as they face a number of strategic decisions around that pipeline," stated Jay Shepard.     

About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

DURECT Forward-Looking Statement
The statements in this press release regarding POSIDUR and its PDUFA date in February 2014, and the potential market introduction of other products in the company's pipeline are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, the risk that the FDA will not complete review of the POSIDUR NDA by the PDUFA date, potential adverse effects arising from additional testing or use of POSIDUR, the potential that the data that we have generated may not be deemed sufficient by FDA or other regulatory agencies to support regulatory approval of POSIDUR, our potential inability to license rights to POSIDUR on commercially acceptable terms, or at all, and the risk of obtaining marketplace acceptance of POSIDUR, avoiding infringing patents held by other parties and securing and defending patents of our own, and managing and obtaining capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on August 6, 2013 under the heading "Risk Factors."

NOTE: POSIDUR, SABER®, TRANSDUR®, and ELADUR are trademarks of DURECT Corporation. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
2. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
3. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
4. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
5. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
6. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
7. DURECT to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
9. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Trianni Announces Launch of Its Optimized Human Antibody Transgenic Mouse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Tillotts Pharma is strengthening its presence in ... office was opened in January 2017 under the management ... ® for the treatment of Crohn,s disease, Asacol ... VistaPrep ® for bowel preparation before endoscopy. With ... on the treatment of gastrointestinal (GI) diseases will expand ...
(Date:2/23/2017)... 23, 2017 The U.S. cannabis market ... for recreational use in 2016. According to a new report ... worth an estimated $7.2 billion in 2016 and is projected ... While adult recreational sales are projected to jump from $2.6 ... 25% CAGR. The market may grow faster as the estimate ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... (PRWEB) February 23, 2017 ... nation to come together to combine its favorite springtime pastime ... favorite fruit – apples! To celebrate National Nutrition Month, the ... “Apple Madness” bracket tournament – a five-week, five-round online competition ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/22/2017)... York, NY (PRWEB) , ... February 22, 2017 ... ... professional life and athletics. It’s enough to overwork even the sharpest brain. , ... that offer peak healthy activity without over clocking the brain. Each capsule contains ...
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, ... largest network of hospitals, health information exchanges, physicians and patients, announced today that ... (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group LLC, an Authorized ...
Breaking Medicine News(10 mins):